RU2008139633A - Лекарственные композиции, содержащие фторхинолоны - Google Patents
Лекарственные композиции, содержащие фторхинолоны Download PDFInfo
- Publication number
- RU2008139633A RU2008139633A RU2008139633/15A RU2008139633A RU2008139633A RU 2008139633 A RU2008139633 A RU 2008139633A RU 2008139633/15 A RU2008139633/15 A RU 2008139633/15A RU 2008139633 A RU2008139633 A RU 2008139633A RU 2008139633 A RU2008139633 A RU 2008139633A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- drug composition
- potassium
- particular sodium
- metabisulfite
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title claims abstract 19
- 239000003814 drug Substances 0.000 title claims abstract 19
- 239000000203 mixture Substances 0.000 title claims abstract 17
- 229940124307 fluoroquinolone Drugs 0.000 title claims abstract 5
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract 6
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract 6
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 claims abstract 4
- 241000894006 Bacteria Species 0.000 claims abstract 4
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims abstract 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims abstract 4
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000003963 antioxidant agent Substances 0.000 claims abstract 4
- 230000003078 antioxidant effect Effects 0.000 claims abstract 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 229960000740 enrofloxacin Drugs 0.000 claims abstract 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 229960002531 marbofloxacin Drugs 0.000 claims abstract 4
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 claims abstract 4
- 235000010263 potassium metabisulphite Nutrition 0.000 claims abstract 4
- 229960001248 pradofloxacin Drugs 0.000 claims abstract 4
- LZLXHGFNOWILIY-APPDUMDISA-N pradofloxacin Chemical compound C12=C(C#N)C(N3C[C@H]4NCCC[C@H]4C3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 LZLXHGFNOWILIY-APPDUMDISA-N 0.000 claims abstract 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims abstract 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims abstract 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims abstract 2
- 108010024636 Glutathione Proteins 0.000 claims abstract 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960004308 acetylcysteine Drugs 0.000 claims abstract 2
- 239000000654 additive Substances 0.000 claims abstract 2
- 229960003405 ciprofloxacin Drugs 0.000 claims abstract 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960002433 cysteine Drugs 0.000 claims abstract 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000018417 cysteine Nutrition 0.000 claims abstract 2
- 229960001305 cysteine hydrochloride Drugs 0.000 claims abstract 2
- 229960003067 cystine Drugs 0.000 claims abstract 2
- FGRVOLIFQGXPCT-UHFFFAOYSA-L dipotassium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [K+].[K+].[O-]S([O-])(=O)=S FGRVOLIFQGXPCT-UHFFFAOYSA-L 0.000 claims abstract 2
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims abstract 2
- 229960003180 glutathione Drugs 0.000 claims abstract 2
- 238000002347 injection Methods 0.000 claims abstract 2
- 239000007924 injection Substances 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims abstract 2
- 229960003151 mercaptamine Drugs 0.000 claims abstract 2
- 229930182817 methionine Natural products 0.000 claims abstract 2
- 229960004452 methionine Drugs 0.000 claims abstract 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000002898 organic sulfur compounds Chemical class 0.000 claims abstract 2
- 229940043349 potassium metabisulfite Drugs 0.000 claims abstract 2
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 claims abstract 2
- 235000019252 potassium sulphite Nutrition 0.000 claims abstract 2
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 claims abstract 2
- 229940001584 sodium metabisulfite Drugs 0.000 claims abstract 2
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims abstract 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims abstract 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940035024 thioglycerol Drugs 0.000 claims abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- -1 thiosorbite Chemical compound 0.000 claims 1
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 abstract 1
- 150000003464 sulfur compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Лекарственная композиция в жидкой форме, содержащая: ! (a) фторхинолон ! (b) антиоксидантное соединение серы ! (c) при необходимости, прочие фармацевтические вспомогательные и/или добавки. ! 2. Лекарственная композиция по п.1, содержащая в качестве антиоксидантного соединения серы сульфит, в частности сульфит натрия, сульфит калия; бисульфит, в частности метабисульфит натрия, метабисульфит калия, пиросульфит калия, пиросульфит натрия, метабисульфит ацетонатрия, бисульфит ацетонатрия; тиосульфат, в частности тиосульфат натрия, тиосульфат калия; или органическое соединение серы, в частности формальдегидсульфоксилат натрия, тиомочевину, тиосорбит, гидрохлорид цистеина, цистин, цистеин, ацетилцистеин, глутатион, цистеамин, метионин, тиоглицерин, тиогликолевую кислоту, тиомолочную кислоту. ! 3. Лекарственная композиция по п.1, содержащая дисульфит натрия. ! 4. Лекарственная композиция по одному из пп.1-3, содержащая в качестве фторхинолона ципрофлоксацин, энрофлоксацин, прадофлоксацин или марбофлоксацин. ! 5. Лекарственная композиция по п.4, содержащая прадофлоксацин. ! 6. Лекарственная композиция по п.4, содержащая энрофлоксацин. ! 7. Лекарственная композиция по п.4, содержащая марбофлоксацин. ! 8. Применение лекарственной композиции по одному из пп.1-7 для получения лекарственных средств для борьбы с заболеваниями, вызванными бактериями. ! 9. Применение по п.8 для получения лекарственных средств, пригодных для инъекций, для борьбы с заболеваниями, вызванными бактериями. ! 10. Применение по п.8 или 9 для получения лекарственных средств с улучшенной переносимостью.
Claims (10)
1. Лекарственная композиция в жидкой форме, содержащая:
(a) фторхинолон
(b) антиоксидантное соединение серы
(c) при необходимости, прочие фармацевтические вспомогательные и/или добавки.
2. Лекарственная композиция по п.1, содержащая в качестве антиоксидантного соединения серы сульфит, в частности сульфит натрия, сульфит калия; бисульфит, в частности метабисульфит натрия, метабисульфит калия, пиросульфит калия, пиросульфит натрия, метабисульфит ацетонатрия, бисульфит ацетонатрия; тиосульфат, в частности тиосульфат натрия, тиосульфат калия; или органическое соединение серы, в частности формальдегидсульфоксилат натрия, тиомочевину, тиосорбит, гидрохлорид цистеина, цистин, цистеин, ацетилцистеин, глутатион, цистеамин, метионин, тиоглицерин, тиогликолевую кислоту, тиомолочную кислоту.
3. Лекарственная композиция по п.1, содержащая дисульфит натрия.
4. Лекарственная композиция по одному из пп.1-3, содержащая в качестве фторхинолона ципрофлоксацин, энрофлоксацин, прадофлоксацин или марбофлоксацин.
5. Лекарственная композиция по п.4, содержащая прадофлоксацин.
6. Лекарственная композиция по п.4, содержащая энрофлоксацин.
7. Лекарственная композиция по п.4, содержащая марбофлоксацин.
8. Применение лекарственной композиции по одному из пп.1-7 для получения лекарственных средств для борьбы с заболеваниями, вызванными бактериями.
9. Применение по п.8 для получения лекарственных средств, пригодных для инъекций, для борьбы с заболеваниями, вызванными бактериями.
10. Применение по п.8 или 9 для получения лекарственных средств с улучшенной переносимостью.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006010642A DE102006010642A1 (de) | 2006-03-08 | 2006-03-08 | Arzneimittelformulierungen, enthaltend Fluorchinolone |
| DE102006010642.3 | 2006-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008139633A true RU2008139633A (ru) | 2010-04-20 |
Family
ID=37907814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008139633/15A RU2008139633A (ru) | 2006-03-08 | 2007-02-23 | Лекарственные композиции, содержащие фторхинолоны |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20090163484A1 (ru) |
| EP (1) | EP1993549A1 (ru) |
| JP (1) | JP2009529014A (ru) |
| KR (1) | KR20080110599A (ru) |
| CN (1) | CN101400351A (ru) |
| AU (1) | AU2007222676A1 (ru) |
| BR (1) | BRPI0708692A2 (ru) |
| CA (1) | CA2644981C (ru) |
| CR (1) | CR10274A (ru) |
| DE (1) | DE102006010642A1 (ru) |
| EC (1) | ECSP088722A (ru) |
| MX (1) | MX2008011489A (ru) |
| NZ (1) | NZ571047A (ru) |
| RU (1) | RU2008139633A (ru) |
| SV (1) | SV2008003018A (ru) |
| WO (1) | WO2007101560A1 (ru) |
| ZA (1) | ZA200807486B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2739249C2 (ru) * | 2010-12-14 | 2020-12-22 | НоваБиотикс Лимитед | Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010069493A1 (de) * | 2008-12-18 | 2010-06-24 | Bayer Animal Health Gmbh | Verbesserte wirkstoffkombination enthaltend ein antibiotikum und einen nichtsteroidalen entzündungshemmer (nsaid) |
| EP2332916A3 (en) | 2009-11-19 | 2011-08-03 | Krka Tovarna Zdravil, D.D., Novo Mesto | A process for a preparation of marbofloxacin and intermediate thereof |
| GB2480276A (en) * | 2010-05-11 | 2011-11-16 | Michael Hilary Burke | Process for the preparation of an aqueous injectable enrofloxacin antimicrobial formulation |
| CN101810569B (zh) * | 2010-05-22 | 2011-09-21 | 鼎正动物药业（天津）有限公司 | 一种恩诺沙星注射液及其制备方法 |
| KR101473979B1 (ko) * | 2013-01-18 | 2014-12-26 | 한국썸벧(주) | 마보플록사신을 포함하는 약제학적 조성물 |
| GR1008168B (el) * | 2013-03-14 | 2014-04-08 | "Φαρματεν Α.Β.Ε.Ε.", | Παρεντερικο σκευασμα αντιβακτηριακου παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου |
| JP6358868B2 (ja) * | 2014-06-17 | 2018-07-18 | Ｄｓファーマアニマルヘルス株式会社 | オルビフロキサシンを含有する製剤組成物 |
| AU2018217931B2 (en) * | 2017-02-13 | 2023-04-13 | Elanco Animal Health Gmbh | Liquid composition containing pradofloxacin |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5746986A (en) * | 1980-09-02 | 1982-03-17 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
| US4670444B1 (en) * | 1980-09-03 | 1999-02-09 | Bayer Ag | and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds |
| US4472405A (en) * | 1982-11-12 | 1984-09-18 | Riker Laboratories, Inc. | Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives |
| US4730000A (en) * | 1984-04-09 | 1988-03-08 | Abbott Laboratories | Quinoline antibacterial compounds |
| DE3517709A1 (de) * | 1985-01-05 | 1986-07-10 | Bayer Ag | Basische zubereitungen von chinoloncarbonsaeuren |
| AT392789B (de) * | 1985-01-23 | 1991-06-10 | Toyama Chemical Co Ltd | Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten |
| US4614572A (en) * | 1985-07-08 | 1986-09-30 | The Dow Chemical Company | Liquid phase chlorination of chlorinated methanes |
| IN166416B (ru) * | 1985-09-18 | 1990-05-05 | Pfizer | |
| KR930001302B1 (ko) * | 1990-12-07 | 1993-02-25 | 주식회사 중외제약 | 시플로플록사신의 주사용 조성물 및 그 제조방법 |
| DE19500784A1 (de) * | 1995-01-13 | 1996-07-18 | Bayer Ag | Enrofloxacin-Injektions- oder Infusionslösungen |
| IL124454A (en) * | 1995-12-21 | 2003-10-31 | Pfizer | Injectable danofloxacin formulations |
| DE19729879C2 (de) * | 1997-07-11 | 1999-07-08 | Mann Gerhard Chem Pharm Fab | Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin |
| US6482799B1 (en) * | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
| EP1121933A1 (en) * | 2000-02-02 | 2001-08-08 | Pfizer Products Inc. | Premixed alatrofloxacin injectable compositions |
| EP1276747A1 (en) * | 2000-04-27 | 2003-01-22 | Pfizer Products Inc. | The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals |
| US7083802B2 (en) * | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| DE102004015981A1 (de) * | 2004-04-01 | 2005-10-20 | Bayer Healthcare Ag | Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| NZ553119A (en) * | 2004-08-13 | 2010-11-26 | Schering Plough Ltd | Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid |
| DE102006010643A1 (de) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
-
2006
- 2006-03-08 DE DE102006010642A patent/DE102006010642A1/de not_active Withdrawn
-
2007
- 2007-02-23 US US12/280,996 patent/US20090163484A1/en not_active Abandoned
- 2007-02-23 KR KR1020087023898A patent/KR20080110599A/ko not_active Application Discontinuation
- 2007-02-23 JP JP2008557621A patent/JP2009529014A/ja not_active Withdrawn
- 2007-02-23 BR BRPI0708692-0A patent/BRPI0708692A2/pt not_active IP Right Cessation
- 2007-02-23 MX MX2008011489A patent/MX2008011489A/es not_active Application Discontinuation
- 2007-02-23 CN CNA2007800082264A patent/CN101400351A/zh active Pending
- 2007-02-23 AU AU2007222676A patent/AU2007222676A1/en not_active Abandoned
- 2007-02-23 NZ NZ571047A patent/NZ571047A/en not_active IP Right Cessation
- 2007-02-23 EP EP07711642A patent/EP1993549A1/de not_active Withdrawn
- 2007-02-23 CA CA2644981A patent/CA2644981C/en not_active Expired - Fee Related
- 2007-02-23 RU RU2008139633/15A patent/RU2008139633A/ru not_active Application Discontinuation
- 2007-02-23 WO PCT/EP2007/001568 patent/WO2007101560A1/de active Application Filing
-
2008
- 2008-09-01 ZA ZA200807486A patent/ZA200807486B/xx unknown
- 2008-09-05 SV SV2008003018A patent/SV2008003018A/es not_active Application Discontinuation
- 2008-09-05 CR CR10274A patent/CR10274A/es not_active Application Discontinuation
- 2008-09-08 EC EC2008008722A patent/ECSP088722A/es unknown
-
2014
- 2014-11-21 US US14/550,877 patent/US20150080387A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2739249C2 (ru) * | 2010-12-14 | 2020-12-22 | НоваБиотикс Лимитед | Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент |
| US11020414B2 (en) | 2010-12-14 | 2021-06-01 | Novabiotics Limited | Antimicrobial compositions with cysteamine |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007222676A1 (en) | 2007-09-13 |
| ECSP088722A (es) | 2008-11-27 |
| US20150080387A1 (en) | 2015-03-19 |
| SV2008003018A (es) | 2009-11-26 |
| NZ571047A (en) | 2012-03-30 |
| MX2008011489A (es) | 2008-11-14 |
| WO2007101560A1 (de) | 2007-09-13 |
| CR10274A (es) | 2009-03-18 |
| KR20080110599A (ko) | 2008-12-18 |
| CA2644981C (en) | 2015-04-28 |
| CA2644981A1 (en) | 2007-09-13 |
| US20090163484A1 (en) | 2009-06-25 |
| ZA200807486B (en) | 2009-11-25 |
| BRPI0708692A2 (pt) | 2011-06-14 |
| EP1993549A1 (de) | 2008-11-26 |
| JP2009529014A (ja) | 2009-08-13 |
| DE102006010642A1 (de) | 2007-09-27 |
| CN101400351A (zh) | 2009-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008139633A (ru) | Лекарственные композиции, содержащие фторхинолоны | |
| EA200970726A1 (ru) | Твердый препарат, содержащий алоглиптин и пиоглитазон | |
| RU2470016C2 (ru) | Производное бипиразола | |
| CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
| Wiliński et al. | Metformin raises hydrogen sulfide tissue concentrations in various mouse organs | |
| ME02015B (me) | Farmaceutski preparati sa (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi- 4-metilfenil]-1-tio-D-glucitolom i sekretagogom insulina | |
| BR0110703A (pt) | Amida, composição farmacêutica que compreende um composto, compostos, utilização de compostos, processos para o tratamento profilático ou terapêutico de diabetes do tipo ii e para a preparação desses compostos | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| CY1113299T1 (el) | Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο | |
| BR0107564A (pt) | Composição de gliburida | |
| PE20040972A1 (es) | Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico | |
| BRPI0407810A (pt) | composto, composição farmacêutica, ativador da glicocinase, e, medicamento | |
| BR112015011179A8 (pt) | composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação | |
| EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| PE20060771A1 (es) | Profarmaco de amida de gemcitabina y composiciones que lo contienen | |
| RU2008129723A (ru) | Ингибиторы ccr9 активности | |
| EA200870183A1 (ru) | Долговременное лечение вич-инфекции | |
| DE602004019405D1 (de) | Pharmazeutische zubereitungen | |
| HRP20110677T1 (hr) | Farmaceutski stabilan spoj koji sadrži timolol, dorzolamid i brimonidin | |
| JP2017514924A5 (ru) | ||
| CY1111460T1 (el) | Μεθανοσουλφονικη 4-[(3-φθοροφαινοξυ) φαινυλο-μεθυλο] πιπεριδινη: χρησεις, διεργασια συνθεσης και φαρμακευτικες συνθεσεις | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| BR0107958A (pt) | Composição farmacêutica contendo pemetrexado juntamente com l-cisteìna monotrioglicerol ou ácido tioglicólico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110328 |